These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 25726752)

  • 1. Speculum versus Bimanual Lid Retraction during Intravitreal Injection.
    Rahimy E; Fineman MS; Regillo CD; Spirn MJ; Hsu J; Kaiser RS; Maguire JI; Brown GC; Chiang A
    Ophthalmology; 2015 Aug; 122(8):1729-30. PubMed ID: 25726752
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessment of ocular pain following ranibizumab intravitreal injection.
    Massamba N; Elluard M; Agoune W; Guyader V; Ingram A; Pasquier B; Knoeri J
    Acta Ophthalmol; 2015 May; 93(3):e231-2. PubMed ID: 25123226
    [No Abstract]   [Full Text] [Related]  

  • 3. Bimanual assisted eyelid retraction technique for intravitreal injections.
    Fineman MS; Hsu J; Spirn MJ; Kaiser RS
    Retina; 2013 Oct; 33(9):1968-70. PubMed ID: 23609121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative assessment of the effectiveness of anaesthesia for intravitreal bevacizumab injection.
    LaHood BR; Sherwood D; Suter A
    Clin Exp Ophthalmol; 2011 Mar; 39(2):184-5. PubMed ID: 21040318
    [No Abstract]   [Full Text] [Related]  

  • 5. ARE INTRAVITREAL INJECTIONS WITH ULTRATHIN 33-G NEEDLES LESS PAINFUL THAN THE COMMONLY USED 30-G NEEDLES?
    van Asten F; van Middendorp H; Verkerk S; Breukink MB; Lomme RM; Hoyng CB; Evers AW; Klevering BJ
    Retina; 2015 Sep; 35(9):1778-85. PubMed ID: 25901838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence of Charles Bonnet syndrome after intravitreal bevacizumab injection in neovascular age-related macular degeneration.
    Zhang H; Liu ZL; Sun P; Gu F
    Acta Ophthalmol; 2012 Dec; 90(8):e647-8. PubMed ID: 22490079
    [No Abstract]   [Full Text] [Related]  

  • 7. Anti-vascular endothelial growth factor injection technique for recurrent exudative macular degeneration in a telescope-implanted eye.
    Joondeph BC
    Retin Cases Brief Rep; 2014; 8(4):342-4. PubMed ID: 25372544
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy.
    Hoang QV; Tsuang AJ; Gelman R; Mendonca LS; Della Torre KE; Jung JJ; Freund KB
    Retina; 2013 Jan; 33(1):179-87. PubMed ID: 22990314
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictors of AMD treatment response.
    Wickremasinghe SS; Sandhu SS; Busija L; Lim J; Chauhan DS; Guymer RH
    Ophthalmology; 2012 Nov; 119(11):2413-2414.e5. PubMed ID: 23122466
    [No Abstract]   [Full Text] [Related]  

  • 10. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
    Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of a flexible dosing regimen of ranibizumab in neovascular age-related macular degeneration: the SUSTAIN study.
    Holz FG; Amoaku W; Donate J; Guymer RH; Kellner U; Schlingemann RO; Weichselberger A; Staurenghi G;
    Ophthalmology; 2011 Apr; 118(4):663-71. PubMed ID: 21459217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
    Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
    Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjunctival flora antibiotic resistance patterns after serial intravitreal injections without postinjection topical antibiotics.
    Hsu J; Gerstenblith AT; Garg SJ; Vander JF
    Am J Ophthalmol; 2014 Mar; 157(3):514-8.e1. PubMed ID: 24332373
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab in advanced-stage neovascular age-related macular degeneration with visual acuity lower than 20/200.
    Parodi MB; Cascavilla M; Papayannis A; Kontadakis DS; Bandello F; Iacono P
    Arch Ophthalmol; 2012 Jul; 130(7):934-5. PubMed ID: 22776937
    [No Abstract]   [Full Text] [Related]  

  • 15. A lack of delayed intraocular pressure elevation in patients treated with intravitreal injection of bevacizumab and ranibizumab.
    Wehrli SJ; Tawse K; Levin MH; Zaidi A; Pistilli M; Brucker AJ
    Retina; 2012 Jul; 32(7):1295-301. PubMed ID: 22466465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
    Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
    Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections.
    Hoang QV; Mendonca LS; Della Torre KE; Jung JJ; Tsuang AJ; Freund KB
    Ophthalmology; 2012 Feb; 119(2):321-6. PubMed ID: 22054994
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic levels of vascular endothelial growth factor before and after intravitreal injection of aflibercept or ranibizumab in patients with age-related macular degeneration: a randomised, prospective trial.
    Zehetner C; Kralinger MT; Modi YS; Waltl I; Ulmer H; Kirchmair R; Bechrakis NE; Kieselbach GF
    Acta Ophthalmol; 2015 Mar; 93(2):e154-9. PubMed ID: 25488124
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
    Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
    Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
    Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
    Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.